It was a busy Friday for Apax Partners. The firm announced an agreement to acquire the operating subsidiaries of Invent Farma, a Spanish manufacturer of generic drugs, and a separate deal to purchase neuraxpharm Arzneimittel, a German producer of treatments for central-nervous-system disorders. Both deals are expected to close in the coming months. Icelandic PE firm Framtakssjóður Íslands was a previous backer of Invent Farma, while Apax will acquire neuraxpharm from ATAX and Neuraxpharm Holding.
The flurry of activity from Apax Partners is hardly a surprise. Even discounting the two agreed-upon acquisitions, Apax has already sealed 19 deals in 2016, according to the PitchBook Platform, well on its way to exceeding last year’s total of 28. That also makes Apax the third most active European-based PE investor so far this year, trailing Ardian and Business Growth Fund. Interestingly, healthcare hasn’t been a key focus for Apax; the sector accounts for less than 8% of activity so far this year after a mere 7% in 2015.
PitchBook Platform users can check out the full list of Europe's most active PE investors. Not a subscriber but interested in getting access? Contact us today.